Upcoming event

EAU21 – Game changing session 4

2021-07-10

Pembrolizumab (pembro) vs. placebo as post nephrectomy adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study

Chairs: U. Capitanio, Milan (IT), P.F.A. Mulders, Nijmegen (NL)

Speaker: T. Powles, London (GB)Discussant: A. Breda, Barcelona (ES)